Compare VHC & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VHC | COCH |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Multi-Sector Companies | Blank Checks |
| Sector | Miscellaneous | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 49.7M |
| IPO Year | 2008 | N/A |
| Metric | VHC | COCH |
|---|---|---|
| Price | $10.42 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 25.4K | ★ 738.0K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $162,000.00 | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3140.00 | N/A |
| 52 Week Low | $9.82 | $0.36 |
| 52 Week High | $29.00 | $1.89 |
| Indicator | VHC | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 31.13 | 48.72 |
| Support Level | N/A | $0.64 |
| Resistance Level | $18.44 | $0.74 |
| Average True Range (ATR) | 1.19 | 0.09 |
| MACD | -0.18 | 0.00 |
| Stochastic Oscillator | 10.46 | 22.33 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. Its software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.